Diversity in Clinical Trials – Background The Federal Drug Administration (FDA) issued non-compulsory guidance on clinical trial diversity to encourage diverse populations in clinical trials and improve the applicability of clinical trial results. The guidance recommends diverse clinical trial populations to better understand the safety and effectiveness of medical products across race, ethnicity, and gender.…
Fargo, ND, October 2022 RxE2 is happy to announce a recent investment from Badlands Capital. “I am so pleased to be working with Badlands Capital, especially since RxE2 is headquartered in Fargo, ND. The Badlands team truly understand what clinical trial innovation looks like and the magnitude of what RxE2 is and will accomplish, as we solve the recruitment, diversity,…
RxE2 is proud to be a member of the PQA, a non-profit organization with 250 diverse members across healthcare. Now more than ever we need to bring the practice of pharmacy into clinical trials. Incorporating PQA programs like Pharmacist Provided Care and Medication Use Quality will change the future outcomes for any clinical trial program…